Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells by Dhodapkar, Madhav V. et al.
Rockefeller University 
Digital Commons @ RU 
Publications Steinman Laboratory Archive 
2005 
Selective blockade of inhibitory Fcγ receptor enables human 
dendritic cell maturation with IL-12p70 production and immunity 
to antibody-coated tumor cells 
Madhav V. Dhodapkar 
Jacob L. Kaufman 
Marc Ehlers 
Follow this and additional works at: https://digitalcommons.rockefeller.edu/steinman-publications 
Selective blockade of inhibitory Fc receptor enables
human dendritic cell maturation with IL-12p70
production and immunity to antibody-coated
tumor cells
Kavita M. Dhodapkar*†, Jacob L. Kaufman*, Marc Ehlers‡§, Devi K. Banerjee*, Ezio Bonvini¶, Scott Koenig¶,
Ralph M. Steinman*, Jeffrey V. Ravetch‡, and Madhav V. Dhodapkar**††‡‡
Laboratories of **Tumor Immunology and Immunotherapy, ‡Molecular Genetics and Immunology, and *Cellular Physiology and Immunology, The
Rockefeller University, New York, NY 10021; ¶MacroGenics, Rockville, MD 20850; §Institute of Molecular Biology (Cancer Research), University of Essen
Medical School, 45147 Essen, Germany; †Department of Pediatrics, New York University Medical Center, New York, NY 10016; and ††Hematology Service,
Memorial Sloan–Kettering Cancer Center, New York, NY 10021
Contributed by Ralph M. Steinman, January 3, 2005
The final differentiation or maturation of dendritic cells (DCs) in
response to environmental stimuli influences their ability to both
initiate immunity and determine the quality of the response to
antigens. Circulating immune complexes and cell-bound immuno-
globulins present in normal human sera represent a potential
stimulus for inadvertent DC activation in the steady state and
during autoimmunity. Here, we show that selective blockade of
the inhibitory Fc receptor (FcR) FcRIIb with recently developed
monoclonal antibodies leads to maturation of human monocyte-
derived DCs, which depends on the presence of IgG in normal
human plasma. Plasma, in the presence of an FcRIIb blockade,
caused the DCs to up-regulate the expression of costimulatory
molecules and to produce the inflammatory mediator IL-12p70.
FcRIIb blockade of DCs loaded with tumor cells led to increased
tumor-specific T cell immunity without the need for exogenous
stimuli other than human plasma. Therefore, the activation status
of DCs in the presence of normal human serum depends on the
balance between activating and inhibitory FcRs and can be
enhanced by new antibodies that react selectively with FcRIIb.
These data suggest an approach for modifying this balance to
enhance immunity to immune complexes and antibody-coated
tumor cells and to silence DC activation by immune complexes in
autoimmune states.
autoimmunity  monoclonal antibody  myeloma  vaccination  cross-
presentation
Dendritic cells (DCs) are highly differentiated antigen-presenting cells that play a key role in the initiation and
regulation of T cell immunity to pathogens and tumors while at
the same time preventing immune responses against self-tissues
or environmental antigens (1, 2). A critical property of DCs is
that their ability to activate or inhibit immunity is linked to
environmental stimuli, which determine their final differentia-
tion or maturation status (3). Several stimuli, such as pathogens
recognized by means of Toll-like receptors, CD40L, heat shock
proteins, inflammatory cytokines, and innate lymphocytes, can
lead to DC maturation and T cell immunity (2). However, under
steady state, DCs must avoid inappropriate activation to prevent
responses to self-antigens (‘‘horror autotoxicus’’) and harmless
environmental antigens (4, 5). Specific pathways that prevent
spontaneous DC activation are not as well understood as mi-
crobial and inflammatory stimuli.
Circulating immune complexes and cell-bound immunoglobu-
lins present in normal human sera represent a potential stimulus
for DC activation in the steady state (6). The physiologic
consequences of cell-bound IgG and immune complexes are
modulated by a balance between activating and inhibitory Fc
receptors (FcRs) and include immune regulatory and inflam-
matory responses (7–10). Engagement of activating FcRs that
contain an immune tyrosine-based activation motif on effector
cells, including monocytes, neutrophils, natural killer cells, and
mast cells, mediates phagocytosis, antibody-dependent cell-
mediated cytotoxicity, and release of cytokines and other in-
f lammatory mediators. In contrast, the inhibitory FcR contains
an immune tyrosine inhibitory motif. Signaling by means of this
receptor leads to recruitment and phosphorylation of an SH2
domain containing inositol polyphosphate 5 phosphatase that
regulates signaling by activating receptors (11, 12). Recent
studies have also shown an important maturation role for FcR
expression on mouse antigen-presenting cells, including DCs
(13). In addition, targeting of antigens to FcRs on human DCs,
including immune complexes and antibody-coated tumor cells,
leads to enhanced generation of both CD4 and CD8 T cell
responses in culture (6, 14–18). Therefore, the targeting of
antigens to DCs by means of immune complexes can mediate
both maturation of DCs and antigen presentation, leading to
immunity that includes cross-presentation of tumors and au-
toantigens to CD8 T cells (17, 19–23).
The FcR system represents a balance of activating and
inhibitory receptors that determines the outcome of immune
complex-mediated inflammation and immunity (24). Prior stud-
ies by Kalergis and Ravetch (25) have shown that targeting
immune complexes to DCs from mice genetically lacking inhib-
itory FcRIIb can lead to enhanced generation of antigen-
specific CD8 T cell immunity in vitro and in vivo. Likewise,
genetic deletion of FcRIIb leads to spontaneous autoimmunity
in genetically prone mice (9). However, the FcR system, i.e.,
both the number and type of activating and inhibitory receptors,
differs significantly between mice and humans (24), and methods
other than genetic deletion are required to manipulate the
balance between activating and inhibitory FcRs. This differ-
ence may complicate the translation of data generated in the
mouse systems to humans. Here, we show that human monocyte-
derived DCs express both activating and inhibitory FcRs. Using
new monoclonal antibodies that selectively block the inhibitory
FcR (M. C. Veri, S. Gorlatov, H. Li, S. Burke, S. Johnson, J.
Stavenhagen, J.V.R., E.B., and S.K., unpublished work), we find
that blockade of this FcR leads to spontaneous and full DC
maturation mediated through activating Ig ligands in normal
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human plasma. Through the aegis of an inhibitory FcR block-
ade, DCs present antigen from antibody-coated tumor cells and
generate tumor-specific T cells without the need for a further
maturation stimulus. These data demonstrate that inhibitory
FcRs have important effects on the function of human DCs and
suggest that DCs are modulated continuously by ligands in
normal human serum.
Materials and Methods
Isolation of DCs. CD14 cells were separated from peripheral
blood mononuclear cells by using CD14 microbeads and columns
(Miltenyi Biotec, Auburn, CA) following the manufacturer’s
protocol and were cultured in RPMI medium 1640 with L-
glutamine (Mediatech, Herndon, VA) supplemented with 1%
single donor plasma GMCSF (20 ngml, Immunex) and IL-4
(12.5 ngml, R & D Systems) to generate DCs. For some
experiments, DC cultures were performed in serum-free media
(AIM-V medium, GIBCO). Additional DC culture media as
controls in some experiments included serum-free media sup-
plemented with 1% plasma or RPMI medium 1640 supple-
mented with Ig-depleted 1% plasma. Igs were depleted from
plasma by using affinity chromatography on a protein G-
Sepharose column (Amersham Biosciences), and depletion was
verified by using SDSPAGE under reducing conditions. For
some experiments, DCs were matured by using an inflammatory
cytokine mixture (26) consisting of IL-1 (10 ngml), IL-6 (1,000
unitsml), and TNF- (10 ngml) (all from R & D Systems) and
prostaglandin E2 (1 gml, Sigma).
To isolate blood-derived DCs, peripheral blood mononuclear
cells were stained with a lineage antibody mixture (Lin-1 FITC,
Becton Dickinson) containing anti-CD3, -CD14, -CD16, -CD19,
-CD20, and -CD56. The lineage negative fraction was isolated by
using anti-FITC magnetic microbeads (per the recommenda-
tions of the manufacturer, Miltenyi Biotec) followed by fluores-
cence-activated cell sorting. Myeloid DCs were identified as
being Lin-1 negative, HLA-DRhigh, and CD11c cells. Plasma-
cytoid DCs were identified as being Lin-1 negative, HLA-DRhigh,
and either CD123 or BDCA2 cells.
FcRIIb-Blocking Antibodies. Antibodies that selectively bind and
block human FcRIIb were obtained from MacroGenics. Initial
experiments used a mouse monoclonal antibody (clone 2B6). In
prior studies, these antibodies reacted specifically with CD32B
and not CD32A, as revealed by ELISA, surface plasmon reso-
nance, and FACS staining of cell lines and transfectants (M. C.
Veri, S. Gorlatov, H. Li, S. Burke, S. Johnson, J. Stavenhagen,
J.V.R., E.B., and S.K., unpublished work). Furthermore, the 2B6
mAb also competed for immune complex binding to the receptor
in an ELISA format and on cells expressing the inhibitory
receptor, and it mediated an inhibitory signal for CD32-
mediated activation in model systems. Additional constructs that
were tested included a human–mouse chimeric antibody (ch-
2B6), as well as an aglycosylated version (agly-2B6) designed to
minimize binding by means of the Fc region of the antibody.
Antibodies were used at a concentration of 1–25 gml, with 1
gml saturating the capacity of 2B6 to induce DC maturation,
which is consistent with prior studies in other test systems.
Blocking Inhibitory FcRs on Human Monocyte-Derived DCs and
Evaluation of Their Maturation. To block inhibitory FcRs, imma-
ture DCs were harvested on day 5 of culture. Up to 2  106 DCs
were suspended in 500 l of DC culture medium and treated for
2 h at 37°C with anti-human FcRIIb-blocking antibody (clone
2B6, 1 gml), IgG1 isotype control antibody (1 gml, Sigma),
or anti-CD16 receptor-blocking antibody (clone 3G8, 1 gml,
Becton Dickinson) or left untreated. After this initial incubation,
additional culture medium was added, and DCs were cultured
overnight at 1  106 DCs per ml. DCs were harvested the next
day to assess DC maturation. The following antibodies were used
for evaluating the surface changes associated with DC matura-
tion: CD11c-APC, CD80-PE, CD83-FITC, CD86-PE, and HLA-
DR-FITC (all from Becton Dickinson). Immature DCs, as well
as DCs matured by using the cytokine mixture, were tested for
the presence of both the inhibitory receptor FcRIIb (by using
anti-FcRIIb antibody 2B6-FITC, MacroGenics) and the acti-
vating FcR FcRIIa (clone IV.3, Medarex, Annandale, NJ).
Using ELISA to Measure the Production of IL-12p70 by DCs. DCs
cultured from purified monocytes were treated with FcRIIb-
blocking antibody or isotype control, as described above. After
overnight culture, supernatants were harvested and analyzed for
the presence of IL-12p70 by ELISA (R & D Systems), following
the manufacturer’s recommendations.
Myeloma Cell Lines. Myeloma cell lines were obtained from the
American Type Culture Collection (U266 cells) or provided by
J. Epstein (Arkansas Cancer Research Center, Little Rock, AR)
(cag cells). Both lines were maintained in RPMI medium 1640
supplemented with 10% FBS.
Loading of Antibody-Coated Dying Tumor Cells on DCs. Immature
DCs were either cultured alone or fed on day 5 of culture with
antibody-coated dying tumor cells, as described in ref. 14. Before
culture, the DCs (4  106 DCs per ml) were either left untreated
or treated with 1 gml FcRIIb-blocking antibody 2B6 or IgG1
isotype control antibody for 30 min at 37°C and then used to load
tumor cells. Tumor cells were labeled with anti-syndecan-1
antibody (B-B4, 1 gml, Serotec) for 30 min at 37°C and then
washed and irradiated to 30 Gy. The irradiated tumor cells were
immediately cocultured with the immature DCs alone (DC-to-
tumor ratio, 1:1; DCs at 0.5  106 cells per ml in 200 l of 5%
pooled human serum) or DCs precoated with FcR-blocking
antibody or isotype control antibody, as above. After 8 h of
coculture, maturation cytokines were added to some of the DC
cultures. DCs were harvested and used for T cell stimulation
after overnight culture with the tumor cells with or without the
addition of maturation cytokines.
Evaluation of Tumor Cell Uptake. To evaluate phagocytosis of dying
tumor cells by DCs, live tumor cells were labeled red with PKH26
(Sigma–Aldrich), and immature DCs were labeled green with
PKH67 (Sigma–Aldrich), as described in ref. 14. The tumor cells
were then coated with anti-syndecan-1 antibody, irradiated, and
cocultured with the dye-labeled DCs (either untreated or treated
with anti-FcRIIb antibody or isotype control) at either 4°C or
37°C. After 4–8 h of coculture, tumor uptake was determined by
evaluating the double positive cells seen by flow cytometry.
Stimulation of T Cells. CD14 blood mononuclear cells were used as
the source of T cells. CD56 cells were depleted from the CD14
cells by using CD56 microbeads (Miltenyi Biotec). CD56-depleted
T cells were stimulated in 24-well flat-bottom plates in RPMI
medium 1640 with L-glutamine supplemented with 5% pooled
human serum. Unpulsed or tumor-loaded DCs were added to the
T cells at a ratio of 1:10–1:30 on days 0 and 7 of culture. IL-2 (25–50
unitsml, Chiron) was added on day 2 and 7 of culture. Cultures
were tested for the presence of tumor-specific T cells 7–10 days after
the last stimulation with DCs.
Evaluation of Tumor-Reactive, IFN--Producing T Cells. The induction
of tumor-reactive, IFN--producing T cells by tumor-loaded
DCs was assessed by using an enzyme-linked immunospot
(ELISPOT) assay, as described in ref. 18. For ELISPOT assay,
105 T cells were cocultured overnight with tumor cells (T
cell-to-tumor cell ratio, 30:1) in ELISPOT plates precoated with
anti-IFN- antibody (MABTECH, Stockholm). To detect pep-









tide-specific T cells, autologous DCs were pulsed with 10 M
HLA A2 restricted peptides derived from MAGE-A3 (271–279,
FLWGPRALV), NY-ESO-1 (157–165, SLLMWITQC), or 2.5
M of an overlapping peptide library (15-mer peptides overlap-
ping by 11 aa) derived from survivin. The peptides were syn-
thesized by the proteomics resource center at The Rockefeller
University. The peptide-pulsed DCs were washed and used as
antigen-presenting cells in the ELISPOT assay, as described in
ref. 14.
Results
Expression of Inhibitory (FcRIIb) and Activating (FcRIIa) FcRs on
Immature and Mature Monocyte-Derived DCs and Blood-Derived DCs.
Prior studies have shown that FcRII is the most common FcR
expressed on human monocyte-derived DCs (17, 20, 22, 27).
However, these studies did not specifically examine the pattern
of activating versus inhibitory isoforms of this receptor. We
therefore used new monoclonal antibodies to the inhibitory
FcRIIb (CD32B) to compare expression of this receptor to the
activating FcRIIa (CD32A) on pure populations of monocyte-
derived (CD14) DCs in the immature stage and after matura-
tion with a cytokine mixture. In prior studies that used ELISA,
surface plasmon resonance, and FACS staining of cell lines and
transfectants to examine the isoform specificity of the recently
developed antibodies, the new antibodies reacted specifically
with CD32B and not CD32A (M. C. Veri, S. Gorlatov, H. Li, S.
Burke, S. Johnson, J. Stavenhagen, J.V.R., E.B., and S.K.,
unpublished work). Immature and mature monocyte-derived
DCs expressed both FcRIIb and FcRIIa by FACS (Fig. 1A).
To confirm the ability of these antibodies to specifically bind the
CD32B and not CD32A on human DCs, we analyzed the staining
patterns by using these antibodies on myeloid (lineage negative,
HLA-DR, and CD11c) and plasmacytoid (lineage negative,
HLA-DR, and CD123BDCA2) subsets of blood DCs.
Plasmacytoid DCs have been shown to express CD32A, but they
lack CD32B at the mRNA level (28). Consistent with this, we
found that plasmacytoid DCs expressed CD32A but did bind the
2B6 mAb to CD32B; in contrast, myeloid DCs stained well with
specific antibodies against both the activating and inhibitory
receptors (Fig. 1B). Thus, myeloid and plasmacytoid subsets of
blood DCs differ in the expression of the activating and inhib-
itory isoforms of FcRII.
Blocking Inhibitory FcRIIb on Immature DCs Leads to a Mature Cell
Surface Phenotype. Serum from otherwise healthy adults can
contain circulating immune complexes (up to 50–100 gml)
that, in principle, may engage FcRs on DCs (29, 30). We
hypothesized that the lack of spontaneous DC maturation during
culture in human plasma was due to coengagement of activation
and inhibitory receptors. To test this hypothesis more directly,
we pretreated DCs cultured under standard conditions in the
presence of 1% normal human plasma and with either a
FcRIIb-blocking antibody (2B6), an FcRIII-blocking anti-
body (3G8), or an isotype control. We then monitored DC
maturation by the up-regulation of surface markers HLA-DR,
CD80, CD86, and CD83. FcRIIb blockade was associated with
up-regulation of CD83, as well as costimulatory molecules
(CD80 and CD86) and HLA-DR. Neither 3G8 or isotype control
resulted in significant up-regulation of these surface markers.
The dose of antibody used in these experiments (1 gml) was
guided by prior studies testing inhibition of immune complex
binding to CD32B. In pilot studies, we also tested higher doses
of antibody, up to 25 gml, which did not result in greater
phenotypic DC maturation (data not shown). Importantly, DC
maturation associated with FcRIIb blockade was seen only
when the DCs were cultured in the presence of human plasma,
not in serumplasma-free media (Fig. 2A). Addition of 1%
plasma to serum-free media reconstituted the DC maturation
seen after FcRIIb blockade (Fig. 2 B and C). Depletion of Ig
from the DC culture media by using a protein G-Sepharose
column attenuated the up-regulation of DC maturation markers
(Fig. 2 D and E). This effect was highly sensitive to the presence
of residual Ig after depletion. The effect of Ig on DC maturation
was still maintained after an initial depletion of 95% of the Ig
in the DC culture medium (data not shown). However, further
depletion of Ig to levels that were undetectable by Western blot
in a 50 concentrated sample (see Western blot in Fig. 2D) led
to an attenuation of DC maturation by human serum. To further
characterize the effects on DC maturation, we used two addi-
tional constructs of the same antibody: a mouse–human chi-
meric antibody (2B6-ch) and an aglycosylated version (2B6-agly)
designed to minimize binding by means of the Fc portion. Results
similar to those obtained with 2B6 were obtained with these 2B6
modified antibodies (Fig. 2E). Thus, the blockade of FcRIIb on
human DCs leads to DC maturation in the presence of activating
Ig ligands in normal human serum.
Blocking Inhibitory FcRIIb on Immature DCs Leads to IL-12 Produc-
tion. Maturation of DCs by ligands for Toll receptors or by
CD40L leads to the secretion of IL-12, a cytokine that plays a
major role in driving CD4 T cells along the T helper 1-type
pathway needed for protection against tumors and pathogens.
Blockade of FcRIIb on pure populations of monocyte-derived
human DCs led to the production of IL-12p70 (Fig. 3). In
contrast, DCs matured by using the inflammatory cytokine
mixture that is commonly used in DC vaccination trials were
poor IL-12p70 producers, as noted in ref. 31, in the presence or
absence of isotype control antibody. These data show that in the
presence of activating ligands present in normal human sera,
simple blockade of inhibitory FcRs induces DCs to secrete
IL-12p70.
Fig. 1. Expression of FcRIIa and FcRIIb on human DCs. (A) Expression of
FcRIIa and FcRIIb on human monocyte-derived DCs. Purified CD14 mono-
cytes were induced to differentiate into DCs in the presence of GMCSF and
IL-4. On day 5 of culture, inflammatory cytokines were added to yield mature
DCs. Expression of FcRIIa and FcRIIb on immature and mature DCs was
determined by flow cytometry by using specific antibodies (IV.3 and 2B6,
respectively). Data are representative of three experiments. (B) Expression of
FcRIIa and FcRIIb on myeloid and plasmacytoid subsets of human blood-
derived DCs. Myeloid (Lin-1, DR, and CD11c) and plasmacytoid (Lin-1,
DR, and CD123BDCA2) DCs were isolated from peripheral blood mono-
nuclear cells as described in Materials and Methods. Expression of FcRIIa and
FcRIIb on immature and mature DCs was determined by flow cytometry by
using specific antibodies (IV.3 and 2B6, respectively). Data are representative
of three experiments.
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Blocking FcRIIb Enhances the Generation of Tumor-Reactive T Cell
Immunity by Tumor-Loaded DCs. DCs can acquire antigen from
tumors or virally infected cells and cross-present antigens from
them to elicit antigen-specific CD8 T cells (32). In prior studies,
we and others have shown that coating tumor cells with antitu-
mor monoclonal antibodies before uptake by human DCs leads
to enhanced cross-presentation (14, 18). This process depends on
the engagement of FcRs on DCs and the addition of a
Fig. 2. Blockade of FcRIIb in the presence of human serum leads to maturation of human monocyte-derived DCs. (A) Monocyte-derived DCs cultured in RPMI
medium 1640 with 1% plasma or serum-free media (AIM-V) were incubated overnight with anti-FcRIIb antibody (2B6, 1 gml) or isotype control antibody.
Expression of HLA-DR, CD80, CD86, and CD83 on CD11c DCs was monitored by flow cytometry. Data are representative of three similar experiments. (B)
Monocyte-derived DCs were cultured either in serum-free medium (AIM-V) or AIM-V supplemented with 1% plasma. DCs were cultured with chimeric (ch-2B6)
anti-FcRIIb antibody or isotype control. DC maturation was monitored by flow cytometry. Data are meanSD of two similar experiments. (C) Representative FACS
plot showing expression of maturation marker CD83CD80 in DCs cultured under conditions described in B. Percentages of CD83 cells are noted. (D)
Monocyte-derived DCs were cultured in either RPMI medium 1640 with 1% plasma or RPMI medium 1640 with 1% Ig-depleted plasma. DCs were cultured with
chimeric (ch-2B6) anti-FcRIIb antibody or isotype control. DC maturation was monitored by flow cytometry. Data shown are meanSD of two similar experiments.
Western blot (Lower) shows depletion of Ig from plasma. Lane 1 is RPMI medium 1640 with 1% plasma, and lane 2 is 50 concentrate of RPMI medium 1640
with 1% Ig-depleted plasma. (E) Representative FACS plot showing expression of maturation marker CD83CD80 in DCs cultured under conditions described in
D, with isotype control or chimeric (ch-2B6) or aglycosylated anti-FcRIIB (agly-2B6) antibody. Percentages of CD83 cells are noted.









maturation stimulus. However, the uptake of antibody-coated
cells likely causes simultaneous engagement of both activating
and inhibitory receptors. Therefore, we tested whether blocking
the inhibitory FcR would alter DC maturation and the gener-
ation of T cell immunity without further stimuli.
First, we tested the effect of blocking FcRIIb on uptake of
tumor cells by DCs. Myeloma tumor cells coated with anti-
syndecan-1 antibody were cultured with immature DCs pre-
treated with either isotype or anti-FcRIIb antibody. Blockade
of FcRIIb did not alter the uptake of tumor cells by DCs (Fig.
4). In prior studies, we did not observe phenotypic DC matu-
ration after uptake of antibody-coated myeloma cells by DCs,
and we reasoned that this effect might be due to simultaneous
engagement of both the activating and inhibitory receptors. In
contrast, blocking FcRIIb led to up-regulation of DC matura-
tion markers (data not shown), consistent with the data pre-
sented above (Fig. 2). If an inflammatory cytokine mixture was
added, these DCs could be induced to undergo more complete
phenotypic maturation with further up-regulation of CD83 (not
shown).
Next, we examined whether blocking FcRIIb leads to stim-
ulation of tumor-specific T cells. In prior experiments, genera-
tion of antitumor immunity by antibody-coated tumor-loaded
DCs required the addition of exogenous maturation stimuli (14,
18). In contrast, under these same conditions, FcRIIb blockade
of DCs led to enhanced stimulation of the T cells, as measured
by IFN- production, even in the absence of additional matu-
ration stimuli (Fig. 5A). Indeed, the presentation of tumor antigens by these DCs was comparable to that elicited by using
DCs that had undergone full maturation using a cytokine
mixture. To further test whether FcRIIb blockade enhanced
the generation of tumor antigen-specific T cells, immature DCs
from HLA-A2 individuals were loaded with A2 cag myeloma
cells and used to stimulate autologous T cells in the presence or
absence of anti-FcRIIb antibody, as described earlier. Cag cells
express high levels of the cancer testis antigens MAGE-A3 and
NY-ESO-1 (14). Therefore, we could evaluate whether FcRIIb
blockade enhances cross-presentation of these specific antigens
by tumor cell-loaded DCs. Stimulation with tumor-loaded DCs
treated with anti-FcRIIb antibody (without any additional
maturation stimulus) led to enhanced T cell responses to defined
A2 restricted epitopes from MAGE-A3, NY-ESO-1, and an
overlapping peptide library derived from a shared tumor anti-
gen, survivin (Fig. 5B).
Discussion
We have shown that blockade of the inhibitory FcR with a
specific monoclonal antibody, 2B6, has a major effect on the
function of human DCs in vitro, thus suggesting that the inhib-
itory FcR is an important component of the regulatory network
that prevents DC maturation in response to naturally occurring
antibodies and immune complexes (ICs). Under steady-state
physiologic conditions, DCs may encounter such ICs either in the
Fig. 3. FcRIIb blockade leads to IL-12p70 production. Supernatants of
immature monocyte-derived DCs treated overnight with anti-FcRIIb (2B6, 1
gml), isotype control antibody, or inflammatory cytokines were analyzed
for IL-12p70 by ELISA.
Fig. 4. Effect of FcRIIb blockade on the uptake of tumor cells by DCs.
Myeloma cells were labeled with dye (PKH26), opsonized with anti-
syndecan-1 antibody, and cocultured with dye (PKH67)-labeled DCs at 4°C or
37°C. DCs were also pretreated with either isotype control antibody or anti-
FcRIIB antibody (2B6). After 4–8 h of coculture, the percentage of double-
positive DCs was evaluated by flow cytometry.
Fig. 5. Effect of FcRIIb blockade on the expansion of myeloma-reactive T
cells by tumor-loaded DCs. (A) Monocyte-derived DCs alone or loaded with
opsonized U266 tumor cells were either left untreated (‘‘no maturation
cytokines’’) or matured ex vivo by using a cytokine mixture as a maturation
stimulus (‘‘with maturation cytokines’’). DCs were also pretreated with either
isotype control or anti-FcRIIb antibody (2B6). The tumor-loaded and un-
pulsed DCs were each used to stimulate autologous T cells. IFN- producers
against U266 (A2) or cag (A2) cells as control were analyzed by ELISPOT
assay. Data shown are meanSD of three separate experiments. (B) Immature
monocyte-derived DCs from HLA-A2 donors were loaded with opsonized cag
(A2) myeloma cells in the presence of isotype control or anti-FcRIIB antibody
(2B6) and used to stimulate autologous T cells. After 14 days of culture, T cells
were stimulated overnight in ELISPOT plates with autologous DCs pulsed with
10 M A2 restricted peptides derived from MAGE-A3, NY-ESO-1, or 2.5 M of
an overlapping 15-mer peptide library derived from survivin. IFN- producers
were quantified by an ELISPOT assay. Data shown are meanSD of four
replicates in independent experiments on two blood donors. *, P value for
comparison with no antigen control. MAGE-A3, P  0.048; NYESO-1 and
survivin, P  0.01.
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circulation or, more likely, as immobilized ICs in lymphoid
tissues (29).
Blockade of the inhibitory FcR is associated not only with
surface remodeling (such as up-regulation of CD8086 costimu-
latory molecules) associated with DC maturation, but also with
the induction of IL-12p70. This cytokine helps DCs to activate
T cell immunity and to polarize responses to the T helper 1
phenotype (2). Indeed, we observed that the blockade of inhib-
itory FcRs on DCs leads to both induction of IL-12p70 and
enhanced tumor-specific, IFN--producing T cells, without the
involvement of other signals from microbial products or innate
lymphocytes. These FcRIIb-blocked DCs are efficient at in-
ducing T cell immunity, even though they have a less mature
phenotype (based on the expression of CD83, HLA-DR, CD80,
and CD86) compared with DCs cultured in the presence of an
inflammatory cytokine mixture.
Our data suggest that immune complexes or naturally occur-
ring autoantibodies in normal human serum (33) are sufficient
to activate human DCs unless the control mechanisms mediated
by inhibitory FcRs are intact. Recent studies have shown that
B cells with specificities against autoantigens are much more
common than previously thought (33). Dysregulation of FcRs
may therefore play an important role in autoimmune diseases
characterized by T helper 1-type T cell immunity. Gershwin and
colleagues (16) have reported that autoantibody complexes are
presented by human DCs to autologous CD8 T cells. Therefore,
a reduction in inhibitory FcRs may lead to DC maturation,
including the production of IL-12 and the induction of immunity,
thereby promoting the amplification of the autoreactive state.
Indeed, polymorphisms in the transmembrane region of
FcRIIb that may restrict inhibitory signaling, as well as poly-
morphisms in FcRIIb’s promoter that result in reduced surface
expression of FcRIIb, have been recently linked to an increased
risk of lupus (34, 35). Recent studies in the mouse suggest a
central role for the expression of this inhibitory receptor on B
cells in maintaining peripheral tolerance (36, 37). The relative
contribution of altered FcRIIb expression on B cells or DCs in
promoting autoimmunity will need to be clarified in future
studies.
Monoclonal antibodies are currently under active investiga-
tion for their therapeutic potential in several cancers. Recent
studies have emphasized the importance of FcRs in effector
functions engaged in vivo by these antibodies (10). The immunity
to antibody-coated tumor cells that follows FcR-mediated
uptake by cultured DCs has suggested the additional possibility
that enhanced T cell immunity may contribute to the antitumor
effects of these antibodies in vivo (14, 18). In this context,
FcRIII and FcRIIa polymorphisms may alter the activation
inhibition ratio by increasing binding affinity to activation re-
ceptors, thereby augmenting DC maturation and stimulation of
antitumor immunity (38, 39). Blockade of FcRIIb leads to the
induction of antitumor immunity without the need for exoge-
nous maturation stimuli and, therefore, may suffice for boosting
T cell responses by means of monoclonal antibodies in vivo. Thus,
these data provide a rationale for blocking inhibitory human
FcRs to improve the efficacy of monoclonal antibodies and to
improve vaccine design, including human DC vaccination against
cancer or infections. Likewise, blockade of activating FcRs
could retard both inflammation and immunization components
of autoimmune diseases.
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